Purpose
Commonly used physical activity metrics tell us little about the intensity distribution across the activity profile. The purpose of this paper is to introduce a metric, the intensity gradient, which can be used in combination with average acceleration (overall activity level) to fully describe the activity profile.
Methods
A total of 1669 adolescent girls (sample 1) and 295 adults with type 2 diabetes (sample 2) wore a GENEActiv accelerometer on their nondominant wrist for up to 7 d. Body mass index and percent body fat were assessed in both samples and physical function (grip strength, Short Physical Performance Battery, and sit-to-stand repetitions) in sample 2. Physical activity metrics were as follows: average acceleration (AccelAV); the intensity gradient (IntensityGRAD from the log–log regression line: 25-mg intensity bins [x]/time accumulated in each bin [y]); total moderate-to-vigorous physical activity (MVPA); and bouted MVPA (sample 2 only).
Results
Correlations between AccelAV and IntensityGRAD (r = 0.39–0.51) were similar to correlations between AccelAV and bouted MVPA (r = 0.48) and substantially lower than between AccelAV and total MVPA (r ≥ 0.93). IntensityGRAD was negatively associated with body fatness in sample 1 (P

Related Links:

The t-SNARE protein SNAP23 conventionally functions as a component of the cellular machinery required for intracellular transport vesicle fusion with target membranes and has been implicated in the regulation of fasting glucose levels, BMI, and type 2 diabetes. Surprisingly, we observed that adipocyte-specific KO of SNAP23 in mice resulted in a temporal development of severe generalized lipodystrophy associated with adipose tissue inflammation, insulin resistance, hyperglycemia, liver steatosis, and early death. This resulted from adipocyte cell death associated with an inhibition of macroautophagy and lysosomal degradatio...

gorta
The prevalence of the so-called diseases of affluence, such as type 2 diabetes or hypertension, has increased dramatically in the last two generations. Although genome-wide association studies (GWAS) have discovered hundreds of genes involved in disease etiology, the sudden increase in disease incidence suggests a major role for environmental risk factors. Obesity constitutes a case example of a modern trait shaped by contemporary environment, although with considerable debates about the extent to which gene-by-environment (G&times;E) interactions accentuate obesity risk in individuals following obesogenic li...

ConclusionsOur data suggest that glucokinase in brain and other non β-cell peripheral hypoglycemia sensors is important in glucose homeostasis, allowing the body to detect and respond to a falling blood glucose.Graphical abstract

GI Dynamics has won a nod from FDA to begin a pivotal trial of the embattled EndoBarrier, a technology used to treat patients with type 2 diabetes. The pivotal trial could be a significant turning point in the life of the Lexington, MA-based company, which was founded in 2004.
The firm has been approved for staged enrollment with initial approval for treatment of up to 67 study participants including 50 EndoBarrier and about 17 control participants. GI Dynamics said it expects to complete enrollment of Stage I of the study during the first half of 2019.
âThis IDE approval is the result of more than two ye...

GI Dynamics (ASX:GID) said today it won FDA investigational device exemption approval to launch a pivotal trial of its EndoBarrier device designed for treating patients with type 2 diabetes and obesity, pending Institutional Review Board approval.
The EndoBarrier device is a plastic gut sleeve designed to prevent the absorption of nutrients from food as it exits the stomach and enters the intestinal tract to treat type 2 diabetes and obesity, the Lexington, Mass.-based company said.
The approval is a boon for the company, which has faced a number of hurdles with its device over the past few years, inclu...